Products image
Home › Products › Cytotoxic antibodies › IPH 4101

IPH 4101

Armand Bensoussan’s team at Henri Mondor Hospital in Créteil, France, discovered that a certain receptor normally present in subpopulations of NK cells was very specifically expressed by tumor cells of a rare form of cutaneous lymphoma, Sezary’s syndrome, an orphan tumor pathology for which there is no effective treatment. This observation led to the development of a cytotoxic antibody directed against this receptor. Through our agreement with the University of Genoa, we gained access to a monoclonal antibody that could be used to generate a drug candidate. We acquired all the rights to the corresponding industrial property elements from the various relevant laboratories and organizations.

 

A drug candidate, IPH 4101, is currently in pre-clinical validation at Innate Pharma for the treatment of rare cutaneous lymphomas such as Sezary Syndrome and Transformed Mycosis Fungoides. Its development is subject to an agreement with the French company Vivalis. This agreement benefits from a significant grant from Oséo (French innovation agency), with Innate Pharma eligible to 3.7 million euroq (about 45% of development cost up to Phase II clinical proof of concept).

 
Market

According to the Cutaneous Lymphoma Foundation, about 1,000 patients worldwide are concerned by Sezary Syndrome and about 20,000 by Mycosys Fongoides. Mycosys Fongoidesis usually a slowly evolving disease but can become aggressive in about 20% of cases (when it becomes a Transformed Mycosys Fongoides). At this stage the disease becomes very aggressive, with debilitating symptoms. Median survival for Sezary Syndrome is about 32 months from diagnosis.
There is therefore a strong medical need for the treatment of this disease.
 
 

Bibliography